Literature DB >> 31519378

C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.

David Bickel1, Holger Gohlke2.   

Abstract

Cells constantly need to adopt to changing environmental conditions, maintaining homeostasis and proteostasis. Heat shock proteins are a diverse class of molecular chaperones that assist proteins in folding to prevent stress-induced misfolding and aggregation. The heat shock protein of 90 kDa (HSP90) is the most abundant heat shock protein. While basal expression of HSP90 is essential for cell survival, in many tumors elevated HSP90 levels are found, which is often associated with bad prognosis. Therefore, HSP90 has emerged as a major target in tumor therapy. The HSP90 machinery is very complex in that it involves large conformational changes during the chaperoning cycle and a variety of co-chaperones. At the same time, this complexity offers a plethora of possibilities to interfere with HSP90 function. The best characterized class of HSP90 modulators are competitive inhibitors targeting the N-terminal ATP-binding pocket. Nineteen compounds of this class entered clinical trials. However, due to severe adverse effects, including induction of the heat shock response, no N-terminal inhibitor has been approved by the FDA so far. As alternatives, compounds commonly referred to as "C-terminal inhibitors" have been developed, either as natural product-based analogues or by rational design, which employ multiple mechanisms to modulate HSP90 function, including modulation of the interaction with co-chaperones, induction of conformational changes that influence the chaperoning cycle, or inhibition of C-terminal dimerization. In this review, we summarize the current development state of characteristic C-terminal inhibitors, with an emphasis on their (proposed) molecular modes of action and binding sites.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C-terminal inhibitors; Drug development; ECGC; HSP90; Novobiocin

Year:  2019        PMID: 31519378     DOI: 10.1016/j.bmc.2019.115080

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  11 in total

1.  Virtual screening based identification of miltefosine and octenidine as inhibitors of heat shock protein 90.

Authors:  Lihong Li; Man Yang; Chenyao Li; Yajun Liu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-18       Impact factor: 3.195

Review 2.  Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years.

Authors:  Ayanda M Magwenyane; Samuel C Ugbaja; Daniel G Amoako; Anou M Somboro; Rene B Khan; Hezekiel M Kumalo
Journal:  Comput Math Methods Med       Date:  2022-05-31       Impact factor: 2.809

3.  Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization.

Authors:  Sanil Bhatia; Lukas Spanier; David Bickel; Niklas Dienstbier; Vitalij Woloschin; Melina Vogt; Henrik Pols; Beate Lungerich; Jens Reiners; Narges Aghaallaei; Daniela Diedrich; Benedikt Frieg; Julian Schliehe-Diecks; Bertan Bopp; Franziska Lang; Mohanraj Gopalswamy; Jennifer Loschwitz; Baubak Bajohgli; Julia Skokowa; Arndt Borkhardt; Julia Hauer; Finn K Hansen; Sander H J Smits; Joachim Jose; Holger Gohlke; Thomas Kurz
Journal:  ACS Cent Sci       Date:  2022-04-27       Impact factor: 18.728

4.  Synthesis of paramagnetic ligands that target the C-terminal binding site of Hsp90.

Authors:  Vishal C Birar; Ioannis Gelis; Ang Zuo; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2020-06-02       Impact factor: 2.823

5.  CDK5RAP3, a Novel Nucleoplasmic Shuttle, Deeply Regulates HSF1-Mediated Heat Stress Response and Protects Mammary Epithelial Cells from Heat Injury.

Authors:  Yangyang Shen; Yan Zou; Jun Li; Fanghui Chen; Honglin Li; Yafei Cai
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

Review 6.  Heat Shock Proteins 90 kDa: Immunomodulators and Adjuvants in Vaccine Design Against Infectious Diseases.

Authors:  Mariana G Corigliano; Valeria A Sander; Edwin F Sánchez López; Víctor A Ramos Duarte; Luisa F Mendoza Morales; Sergio O Angel; Marina Clemente
Journal:  Front Bioeng Biotechnol       Date:  2021-01-20

Review 7.  Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases.

Authors:  Lisha Wang; Liza Bergkvist; Rajnish Kumar; Bengt Winblad; Pavel F Pavlov
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

Review 8.  With or without You: Co-Chaperones Mediate Health and Disease by Modifying Chaperone Function and Protein Triage.

Authors:  Selin Altinok; Rebekah Sanchez-Hodge; Mariah Stewart; Kaitlan Smith; Jonathan C Schisler
Journal:  Cells       Date:  2021-11-11       Impact factor: 7.666

Review 9.  Heat Shock Protein 90 (Hsp90) and Hsp70 as Potential Therapeutic Targets in Autoimmune Skin Diseases.

Authors:  Stefan Tukaj; Krzysztof Sitko
Journal:  Biomolecules       Date:  2022-08-20

Review 10.  Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases.

Authors:  Monimoy Banerjee; Ishita Hatial; Bradley M Keegan; Brian S J Blagg
Journal:  Pharmacol Ther       Date:  2020-11-24       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.